LIXIL-FOUNDATION
28.10.2016 07:02:53 CEST | Business Wire | Press release
The LIXIL Foundation (located in Koto-ku, Tokyo; Chairman: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, is pleased to announce today that the next-generation sustainable housing “INFINITE FIELD” designed by The Royal Danish Academy of Fine Arts (Denmark) has been completed on a site of Memu Meadows in Taiki-cho Hokkaido, environmental technology research facilities managed by the foundation.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161027007034/en/
INFINITE FIELD is the top prize winner in the 6th LIXIL International Student Architectural Competition sponsored by the LIXIL Foundation, aimed to seek and review next-generation sustainable housing technology and communicate that technology to the global community. The project was designed based on the theme: “Comfort and Lightness.” For the first time in its history, this year’s competition called for proposals for a light shelter that can be easily assembled and moved.
INFINITE FIELD is a structure that features a 360-degree timber platform and the design enveloped by soft, permeable membranes. From this elevated platform, which is aligned with an average snow depth in this region, users are able to enjoy the view of snowfield spreading infinitely during the winter months while the platform transforms into a place to cool off in the summer heat. It is designed to allow people to feel changes of the seasons in Taiki-cho.
The varied textile membranes invite nature in and allow the architecture in itself to move. The fabric is layered to create the space; these textiles are chosen with consideration of various environmental properties to ensure a comfortable thermal environment. Dwellers can operate these layered membranes on their own, adding or removing them to adjust their relationships with the environment while they serve as an expanded threshold.
With the completion of INFINITE FIELD, Memu Meadows is now a home to six structures designed by students. The effects of these “next-generation sustainable houses” will continue to be verified.
|
Accompanying Material |
||||||||
|
-- INFINITE FIELD designed by The Danish Royal Academy of Fine Arts (Denmark) |
||||||||
|
Supervisor: |
Anders Brix, Professor | |||||||
|
Students: |
Kazumasa Takada/Bas Spaanderman | |||||||
| Scarlett Emma Hessian/Jesse Thomas | ||||||||
| Benjamin Hock Yuu Tan/Konstantinos Fetsis | ||||||||
|
Design Supervisor: Kengo Kuma & Associates |
Structural Engineer: Oak Structural Design |
|
|
General Contractor: Takahashi Construction Company |
Building Area: 21.3m2 |
|
|
Construction Cost: Approx. 15 million yen |
||
|
Construction Period: August 2016 - October 2016 |
||
[Features]
-
Seasonal Transformation
INFINITE FIELD was imagined as a permeable experience, one where users are able to dictate their conditions, while engaging with the natural environment surrounding them. During the winter months it is from this elevated vantage point that users are aligned with an infinite sea of snow, and are treated to overlook the landscape from the warmth of the nest. In the summer heat the platform transforms into a place for rest and quiet reflection, looking out to a field of wild grasses, trees and bright blue skies. This 360-degree timber base is a contemplative oasis providing panoramic views of the natural surrounding. -
Spatial Tactility
INFINITE FIELD is an architecture of change and graduation, allowing users to experience and enjoy the shifting environment in comfort, while simultaneously enhancing our human connection with nature. A set of soft, permeable membranes made of varied textiles invites nature in and allows the design to move and breathe with the seasons. As you transition across the platform users can operate the membranes, moving them to add or remove barriers between the environment and themselves. These layers are an expanded threshold, an envelope inviting nature in while allowing a tactile interaction with the architecture. -
Material
Dwelling
The fabric architecture imparts a whole new perspective to familiar scenes. Silk fabric blades hang from the draped inner membrane disrupting heat and air flow. Users are able to visually perceive the gentle winds and air that flow through the dwelling as these fabric blades gently sway and flutter in the breeze. The project’s textiles are chosen with consideration of the various environmental properties, while their layered design provides adaptable thermal zones for user’s personal comfort.
-- Overview of Facility
Name:
Memu Meadows
Location:
158-1 Memu, Taiki-cho, Hiro-gun, Obihiro, Hokkaido
Owner:
LIXIL Foundation 2-1-1 Ojima, Koto-ku, Tokyo, 136-8535
Site
area:
App. 184,000 square meters
Main facilities:
Experimental
house “Même”, “Mock-up of Multiple floor Bamboo House”, “A recipe to
live”, “BARN HOUSE”, “HORIZON HOUSE”, “NEST WE GROW”, “INVERTED HOUSE”,
Multipurpose Facility, Conference Pavilion, Residence 1L and 1R
(accommodation for researchers), two log houses (accommodation for
researchers), fitness center, restaurant, Administration Wing, etc.
Official
website:
http://www.lixiljsfound.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007034/en/
Contact:
LIXIL Foundation
Kenji Iida, +81-3-5626-1008
2-1-1, Oshima,
Koto-ku, Tokyo 136-8535
Fax: +81-3-5626-1033
LIXIL Foundation
website: http://www.lixiljsfound.com/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
